In partnership with the
University of Texas M.D. Anderson
Cancer Center



Our Pipeline includes more than 15 molecular imaging and therapeutic agents.

Read More.

R & D

Cell>Point has entered into long-term commitments to financially sponsor and support continuing research and development at M. D. Anderson Cancer Center for the EC Technology, Beta Cell, In-Situ Hydrogel, N4 Technology, and Dual Agent Technology platforms.

Read More.


Cell>Point is pursuing an aggressive domestic and international patent protection program for each of the licensed technologies.

Read More.